Beam Therapeutics is a company that makes medicines for people who have certain health problems because of their genes. They are testing a new medicine called BEAM-302 to see if it can help people with a condition called AATD, which can make them very sick in the lungs and liver. This test will show how much of the medicine they need to take. Another problem that some people have is glycogen storage disease 1a, and Beam Therapeutics is also making another medicine called BEAM-301 to help with that. They are getting ready to try it out in a test soon. Read from source...

1. The article title is misleading and does not accurately reflect the content of the article. It implies that BEAM Therapeutics has started dosing patients in a phase I/II study for AATD, which is true, but it also suggests that this is a major breakthrough or milestone in the development of BEAM-302, when in fact it is just one step in the process. The article should have been more specific and clear about what stage of the clinical trial the company is at and what are the implications for the future of BEAM-302.